Abstract
Aim: To assess the experience with the PET/ MRI and PET/CT with the application of 68 Ga-PSMA-11 in patients with diagnostics of prostatic carcinoma, the assessment targeted the logistic, safety, and the inclusion of 68 Ga-PSMA-11 into the diagnostic work-up. Method: 500 examinations with the application of68Ga-PSMA-11 were performed between January 2018 and December 2020, there were 200 of PET/CT and 300 of PET/MRI in 449 male patients, in 43 of them were performed multiple examinations.68Ga-PSMA-11 into was injected using activity dosing of 1.25 MBq per kilogram of body weight.
PET/CT examinations were performed in the extent of trunk and head except those indicated to radioligand therapy or biochemical relapse, when it was used the whole-body examination. In PET/MRI, the targeted pelvic imaging was performed before the trunk and head examinations, with the exception of cases when the radical prostatectomy was used, then the targeted examination was targeted.
Results: No serious complication related to the application of68Ga-PSMA-11 were registered. In PET/CT, the most frequent indication was restaging during therapy (53%, 106 cases), followed by the staging examination (31%, 62 examinations), in opposite PET/MRI was indicated most often due to the staging (67%, 201 examinations), restaging in 20% (60 examinations), respectively.
The ration of particular examinations and also percentage was almost equal in indication of biochemical relapse (PET/CT in 22 cases, 11%, PET/MRI in 8%, 24 examinations). Conclusion:68Ga-PSMA-11 is safe and valuable radiopharmaceutical in staging, restaging and assessment of the therapy response in patients with prostatic carcinoma.
When the availability of PET/CT and PET/MRI is the equal, PET/MRI is preferred in staging of the disease, in opposite side, PET/CT in the assessment of the effect of therapy or restaging. (C) 2021, Galen s.r.o.. All rights reserved.